REGISTERED NUMBER: 07259684 (England and Wales)

Pharma Plus Medical Ltd

Unaudited Financial Statements

for the period

31st May 2024 to 29th November 2025

Page

Company information

1

Balance sheet

2

to

3

Notes to the financial statements

4

to

6

Directors:

S N H Shah

Mrs S P Shah

Secretary:

S N H Shah

Registered office:

4 Abbey Meadows

Morpeth

Northumberland

NE61 2BD

Registered number:

07259684 (England and Wales)

Accountants:

Rennie Welch LLP

Academy House

Shedden Park Road

Kelso

Roxburghshire

TD5 7AL

Fixed assets

Tangible assets

4

-

5,950

Current assets

Stocks

-

40,000

Debtors

5

92,132

480,643

Cash at bank

80

79,687

92,212

600,330

Creditors

Amounts falling due within one year

6

159,205

396,176

Net current (liabilities)/assets

(66,993

)

204,154

Total assets less current liabilities

(66,993

)

210,104

Creditors

Amounts falling due after more than one year

7

-

68,345

Net (liabilities)/assets

(66,993

)

141,759

Capital and reserves

Called up share capital

1,000

1,000

Retained earnings

(67,993

)

140,759

(66,993

)

141,759

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 29th November 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 29th November 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of income and retained earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 22nd June 2026 and were signed on its behalf by:

S N H Shah - Director

1.	Statutory information

Pharma Plus Medical Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	Accounting policies

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for pharmacy goods and services, excluding discounts, rebates, value added tax and other sales taxes.

Turnover arising from the sale of goods is recognised when the significant risks and rewards of ownership have passed to the buyer.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Motor vehicles

-

Straight line over 5 years

Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.

Stocks

Stock is valued at the lower of cost and estimated selling price less costs to sell and after making due allowance for obsolete and slow moving items.

Financial instruments

The following assets and liabilities are classified as financial instruments - other loans, trade debtors, inter-company loans, trade creditors, accruals and directors' loans.

Other loans are initially measured at the present value of future payments, discounted at a market rate of interest, and subsequently at amortised cost using the effective interest method.

Directors' loans (being repayable on demand), inter-company loans, trade debtors, trade creditors and accruals are measured at the undiscounted amount of the cash or other consideration expected to be paid or received.

Financial assets that are measured at amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Income and Retained Earnings.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Provisions

Provisions are set up only where it is probable that a present obligation exists as a result of an event prior to the balance sheet date and that a payment will be required in settlement that can be estimated reliably. Where material, provisions are calculated on a discounted basis.

Employee benefits

Short term employee benefits, including holiday pay, are recognised as an expense in the Statement of Income and Retained Earnings in the period in which they are incurred.

Going concern

Due to operational and staffing issues the company has ceased trading. It is the intention of the director to have the company wound up once its affairs have been put in order.

3.	Employees and directors

The average number of employees during the period was 11 (2024 - 9 ) .

4.	Tangible fixed assets

Motor

vehicles

£

Cost

At 31st May 2024

14,308

Disposals

(14,308

)

At 29th November 2025

-

Depreciation

At 31st May 2024

8,358

Charge for period

2,100

Eliminated on disposal

(10,458

)

At 29th November 2025

-

Net book value

At 29th November 2025

-

At 30th May 2024

5,950

5.

Debtors: amounts falling due within one year

2025

2024

£

£

Trade debtors

-

120,426

Amounts owed by group undertakings

3,912

3,912

Other debtors

88,220

356,305

92,132

480,643

6.

Creditors: amounts falling due within one year

2025

2024

£

£

Bank loans and overdrafts

-

71,435

Trade creditors

18,226

122,697

Amounts owed to group undertakings

61,767

61,057

Taxation and social security

77,112

98,590

Other creditors

2,100

42,397

159,205

396,176

7.

Creditors: amounts falling due after more than one year

2025

2024

£

£

Bank loans

-

68,345

8.	Directors' advances, credits and guarantees

The following advances and credits to the director subsisted during the years ended 29th November 2025 and 30th May 2024:

2025

2024

Director

Balance outstanding at start of year

232,689

-

Amounts advanced

-

744,789

Amount repaid

(232,689

)

(512,100

)

-

232,689

This loan is unsecured, interest has been charged at the official rates published by HMRC and it is repayable on demand.

9.	Ultimate controlling party

Pharma Plus Medical Ltd is the wholy owned subsidiary of Health Hut Professionals Ltd a small company registered in England and Wales.